Equity Overview
Price & Market Data
Price: $0.751
Daily Change: +$0.0155 / 2.06%
Daily Range: $0 - $0
Market Cap: $3,985,212
Daily Volume: 0
Performance Metrics
1 Week: 7.25%
1 Month: -14.36%
3 Months: -23.53%
6 Months: -12.92%
1 Year: -50.64%
YTD: -31.39%
Details
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat gout and progressive kidney disease. Its drug development programs include XRx-026, which is in the third phase for the treatment of gout; XRx-008, which is in the second phase to treat autosomal dominant polycystic kidney disease; XRx-101, which is in the second phase to treat acute kidney injury associated with respiratory virus infection; and XRX-225, which is in the preclinical stage for the treatment of type 2 diabetic nephropathy. It has a license agreement with the University of Florida Research Foundation, Inc. for the use of uric acid lowering agent to treat insulin resistance. The company is based in Calgary, Canada.